SCHEMBL3767147

SCHEMBL3767147

Cc1ccccc1C(=O)Nc1cccc(C(=O)NC2CCCCCC2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.67
NPC1 O15118 6/20 0.67
KCNK3 O14649 2/20 0.61
KCNK9 Q9NPC2 2/20 0.61
ACKR3 P25106 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 1/20 0.57
PKM P14618 2/20 0.57
ALOX15 P16050 1/20 0.57
HTR2B P41595 1/20 0.57
POLB P06746 1/20 0.57
KMT2A Q03164 2/20 0.55
KIT P10721 1/20 0.55
LMNA P02545 1/20 0.55
KDM4E B2RXH2 1/20 0.54
GFER P55789 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SMYD3 Q9H7B4 1/20 0.54
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764438 0.87 HTR2B (0.58) RAB9ANPC1KCNK3KCNK9SMN1; SMN2
SCHEMBL3771105 0.86 RAB9A (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1PKM
SCHEMBL3766917 0.86 F2R (0.63) RAB9ANPC1ALDH1A1PKMALOX15
SCHEMBL3775418 0.86 ACKR3 (0.61) RAB9ANPC1KCNK3KCNK9ACKR3
SCHEMBL3764424 0.86 HTR2B (0.63) RAB9ANPC1ACKR3SMN1; SMN2PKM
SCHEMBL3766555 0.86 HTR2B (0.57) RAB9ANPC1SMN1; SMN2PKMALOX15
SCHEMBL3771747 0.85 KCNK3 (0.63) RAB9ANPC1KCNK3KCNK9ACKR3
SCHEMBL3766651 0.83 PKM (0.55) RAB9ANPC1KCNK3KCNK9ACKR3
SCHEMBL3771553 0.83 KCNK3 (0.63) KCNK3KCNK9HTR2B
SCHEMBL8198182 0.82 NPC1 (1.00) RAB9ANPC1SMN1; SMN2ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324086-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2010-12-23 US claimed
WO-2009103778-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2009-08-27 WO claimed
US-20100324086-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2010-12-23 US disclosed
WO-2009103778-A1 COMPOUNDS AND METHODS NOVASAID AB (SE) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324086-A1 COMPOUNDS AND METHODS IL1B, LITAF, CYP11B1 RAB9A 2083/4885NPC1 145/4885KCNK3 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.